Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
0.831 USD +2.59% Intraday chart for Hyperfine, Inc. +2.59% -25.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study CI
Wells Fargo Trims Hyperfine's Price Target to $1.60 From $2.10, Keeps Equalweight Rating MT
B. Riley Trims Hyperfine's PT to $1.30 From $1.70 After 'Disappointing' Q4 2023 Sales, 2024 Guidance; Maintains Buy Rating MT
Transcript : Hyperfine, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Earnings Flash (HYPR) HYPERFINE Posts Q4 Revenue $2.7M MT
Hyperfine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Hyperfine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Hyperfine, Inc. and Athletic Heart Cardiac and Metabolic Testing, Llc Announce Collaboration to Bring Portable Brain Imaging Screening to Current and Former Professional Athletes CI
Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use CI
Jefferies Starts Hyperfine With Hold Rating MT
Transcript : Hyperfine, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Hyperfine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (HYPR) HYPERFINE Reports Q3 Revenue $2.3M, vs. Street Est of $2.95M MT
Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023 CI
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday MT
Top Premarket Decliners MT
Hyperfine Says US FDA Clears Updated AI-Powered Swoop System Software MT
Hyperfine, Inc. Announces the Termination of Khan Siddiqui as Chief Medical Officer and Chief Strategy Officer CI
Hyperfine, Inc.(NasdaqGM:HYPR) added to S&P Global BMI Index CI
B. Riley Lifts Hyperfine's Price Target to $3.50 From $2.50 After Higher-Than-Expected Q2 Results, Keeps Buy Rating MT
Transcript : Hyperfine, Inc., Q2 2023 Earnings Call, Aug 14, 2023
Hyperfine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (HYPR) HYPERFINE Reports Q2 Revenue $3.4M, vs. Street Est of $2.8M MT
Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023 CI
Chart Hyperfine, Inc.
More charts
Hyperfine, Inc. is a health technology company. The Company provides a Swoop Portable Magnetic Resonance Imaging System (Swoop system), which is a portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. Its Swoop system produces images at a lower magnetic field strength than conventional MRI scanners. The Swoop system is a portable, ultra-low-field (ULF) MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. MRI is used in various clinical settings for medical diagnosis, the staging of disease, and follow-up treatment. It has designed Swoop system to address an unmet need in point-of-care medical imaging through a combination of hardware and artificial intelligence (AI)-powered software services. The Company’s system operates from a Wi-Fi-capable tablet and integrates with picture archiving and communication systems (PACS).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.831 USD
Average target price
1.3 USD
Spread / Average Target
+56.44%
Consensus
  1. Stock Market
  2. Equities
  3. HYPR Stock
  4. News Hyperfine, Inc.
  5. Hyperfine Shares Tumble Following Wells Fargo Downgrade, Q2 Revenue Miss